NPJ breast cancer

Keyphrases

Publications

volume 10, number 1, 2024

Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, Bjørn-Erik Bertelsen, Debora Macis, Davide Serrano, Gunnar Mellgren, Matteo Lazzeroni, Parijatham S Thomas, Katherine D Crew, Nagi B Kumar, Irene Maria Briata, Viviana Galimberti, Giuseppe Viale, Lana A Vornik, Valentina Aristarco, Tania Buttiron Webber, Stefano Spinaci, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea Decensi
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. NPJ breast cancer 10 (1) (2024)
L M Janssen, Markus H A Janse, B B L Penning de Vries, B H M van der Velden, E J M Wolters-van der Ben, S M van den Bosch, A Sartori, C Jovelet, M J Agterof, D Ten Bokkel Huinink, E W Bouman-Wammes, P J van Diest, E van der Wall, S G Elias, Kenneth G A Gilhuijs
Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Elena Zaikova, Brian Y C Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Tamara Shenkier, Christine Simmons, Sara Taylor, Diego Villa, Ruth Miller, Rosalia Aguirre-Hernandez, Samuel Aparicio, Karen A Gelmon
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. NPJ breast cancer 10 (1) (2024)
Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, Bjørn-Erik Bertelsen, Debora Macis, Davide Serrano, Gunnar Mellgren, Matteo Lazzeroni, Parijatham S Thomas, Katherine D Crew, Nagi B Kumar, Irene Maria Briata, Viviana Galimberti, Giuseppe Viale, Lana A Vornik, Valentina Aristarco, Tania Buttiron Webber, Stefano Spinaci, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea Decensi
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. NPJ breast cancer 10 (1) (2024)
L M Janssen, Markus H A Janse, B B L Penning de Vries, B H M van der Velden, E J M Wolters-van der Ben, S M van den Bosch, A Sartori, C Jovelet, M J Agterof, D Ten Bokkel Huinink, E W Bouman-Wammes, P J van Diest, E van der Wall, S G Elias, Kenneth G A Gilhuijs
Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. NPJ breast cancer 10 (1) (2024)
Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Joan C Lo, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ breast cancer 10 (1) (2024)
Andrea Favero, Ilenia Segatto, Alessandra Capuano, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, Lorena Musco, Sara D'Andrea, Alessandra Dall'Acqua, Chiara Gava, Tiziana Perin, Samuele Massarut, Cristina Marchini, Gustavo Baldassarre, Paola Spessotto, Barbara Belletti
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice. NPJ breast cancer 10 (1) (2024)
Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T A Van der Graaf, Wim J G Oyen, Danielle J Vugts, C Willemien Menke-van der Houven van Oordt, Adrienne H Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Jean L Wright, Robert Gray, Habib Rahbar, Christopher E Comstock, Judy A Tjoe, Sunil S Badve, Abram Recht, Joseph A Sparano, Nancy E Davidson, Antonio C Wolff
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. NPJ breast cancer 10 (1) (2024)
Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Joan C Lo, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ breast cancer 10 (1) (2024)
Pei Meng, Hina Dalal, Yilun Chen, Christian Brueffer, Sergii Gladchuk, Miguel Alcaide, Anna Ehinger, Lao H Saal
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab. NPJ breast cancer 10 (1) (2024)
Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, Bjørn-Erik Bertelsen, Debora Macis, Davide Serrano, Gunnar Mellgren, Matteo Lazzeroni, Parijatham S Thomas, Katherine D Crew, Nagi B Kumar, Irene Maria Briata, Viviana Galimberti, Giuseppe Viale, Lana A Vornik, Valentina Aristarco, Tania Buttiron Webber, Stefano Spinaci, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea Decensi
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. NPJ breast cancer 10 (1) (2024)
Jie Mei, Yun Cai, Hongjun Zhu, Ying Jiang, Ziyi Fu, Junying Xu, Lingyan Chen, Kai Yang, Jinlu Zhao, Chenghu Song, Yan Zhang, Wenjun Mao, Yongmei Yin
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula, Virginia G Kaklamani
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ breast cancer 10 (1) (2024)
Emily Jane Gallagher, Heather B Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus DaSilva Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N Hortobagyi, Benjamin H Kaffenberger, Bernice Y Kwong, Timothy Pluard, Ruta Rao, Lee Schwartzberg, Michael S Broder
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ breast cancer 10 (1) (2024)
Andrea Favero, Ilenia Segatto, Alessandra Capuano, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, Lorena Musco, Sara D'Andrea, Alessandra Dall'Acqua, Chiara Gava, Tiziana Perin, Samuele Massarut, Cristina Marchini, Gustavo Baldassarre, Paola Spessotto, Barbara Belletti
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice. NPJ breast cancer 10 (1) (2024)
Isabelle Grootes, Gordon C Wishart, Paul David Peter Pharoah
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy. NPJ breast cancer 10 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, Bjørn-Erik Bertelsen, Debora Macis, Davide Serrano, Gunnar Mellgren, Matteo Lazzeroni, Parijatham S Thomas, Katherine D Crew, Nagi B Kumar, Irene Maria Briata, Viviana Galimberti, Giuseppe Viale, Lana A Vornik, Valentina Aristarco, Tania Buttiron Webber, Stefano Spinaci, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea Decensi
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. NPJ breast cancer 10 (1) (2024)
Elena Zaikova, Brian Y C Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Tamara Shenkier, Christine Simmons, Sara Taylor, Diego Villa, Ruth Miller, Rosalia Aguirre-Hernandez, Samuel Aparicio, Karen A Gelmon
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. NPJ breast cancer 10 (1) (2024)
Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T A Van der Graaf, Wim J G Oyen, Danielle J Vugts, C Willemien Menke-van der Houven van Oordt, Adrienne H Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Jean L Wright, Robert Gray, Habib Rahbar, Christopher E Comstock, Judy A Tjoe, Sunil S Badve, Abram Recht, Joseph A Sparano, Nancy E Davidson, Antonio C Wolff
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Silver Alkhafaji, Denise M Wolf, Mark Jesus M Magbanua, Laura van 't Veer, John W Park, Laura J Esserman, Rita A Mukhtar
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. NPJ breast cancer 10 (1) (2024)
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Pei Meng, Hina Dalal, Yilun Chen, Christian Brueffer, Sergii Gladchuk, Miguel Alcaide, Anna Ehinger, Lao H Saal
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab. NPJ breast cancer 10 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Hui Liu, Xiaodong Xie, Bin Wang
Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images. NPJ breast cancer 10 (1) (2024)
Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Joan C Lo, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ breast cancer 10 (1) (2024)
Emily Jane Gallagher, Heather B Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus DaSilva Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N Hortobagyi, Benjamin H Kaffenberger, Bernice Y Kwong, Timothy Pluard, Ruta Rao, Lee Schwartzberg, Michael S Broder
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ breast cancer 10 (1) (2024)
Jie Mei, Yun Cai, Hongjun Zhu, Ying Jiang, Ziyi Fu, Junying Xu, Lingyan Chen, Kai Yang, Jinlu Zhao, Chenghu Song, Yan Zhang, Wenjun Mao, Yongmei Yin
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Emily Jane Gallagher, Heather B Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus DaSilva Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N Hortobagyi, Benjamin H Kaffenberger, Bernice Y Kwong, Timothy Pluard, Ruta Rao, Lee Schwartzberg, Michael S Broder
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ breast cancer 10 (1) (2024)
Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Joan C Lo, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ breast cancer 10 (1) (2024)
L M Janssen, Markus H A Janse, B B L Penning de Vries, B H M van der Velden, E J M Wolters-van der Ben, S M van den Bosch, A Sartori, C Jovelet, M J Agterof, D Ten Bokkel Huinink, E W Bouman-Wammes, P J van Diest, E van der Wall, S G Elias, Kenneth G A Gilhuijs
Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. NPJ breast cancer 10 (1) (2024)
Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Joan C Lo, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ breast cancer 10 (1) (2024)
Silver Alkhafaji, Denise M Wolf, Mark Jesus M Magbanua, Laura van 't Veer, John W Park, Laura J Esserman, Rita A Mukhtar
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. NPJ breast cancer 10 (1) (2024)
Isabelle Grootes, Gordon C Wishart, Paul David Peter Pharoah
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy. NPJ breast cancer 10 (1) (2024)
Isabelle Grootes, Gordon C Wishart, Paul David Peter Pharoah
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy. NPJ breast cancer 10 (1) (2024)
Hui Liu, Xiaodong Xie, Bin Wang
Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images. NPJ breast cancer 10 (1) (2024)
Hui Liu, Xiaodong Xie, Bin Wang
Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images. NPJ breast cancer 10 (1) (2024)
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula, Virginia G Kaklamani
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ breast cancer 10 (1) (2024)
Andrea Favero, Ilenia Segatto, Alessandra Capuano, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, Lorena Musco, Sara D'Andrea, Alessandra Dall'Acqua, Chiara Gava, Tiziana Perin, Samuele Massarut, Cristina Marchini, Gustavo Baldassarre, Paola Spessotto, Barbara Belletti
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice. NPJ breast cancer 10 (1) (2024)
Mengting Chen, Shibo Yu, Tineke van der Sluis, Mieke C Zwager, Carolien P Schröder, Bert Van der Vegt, Marcel A T M van Vugt
cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ breast cancer 10 (1) (2024)
Mengting Chen, Shibo Yu, Tineke van der Sluis, Mieke C Zwager, Carolien P Schröder, Bert Van der Vegt, Marcel A T M van Vugt
cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ breast cancer 10 (1) (2024)